Ruiyan Wu

Years Active: 2021-2024
Publications (10 Years): 2

This page only lists publications with an associated author ORCID identifier.

Publications

Fan Xia, Yaqi Wang, Hui Wang, Lijun Shen, Zuolin Xiang, Yutian Zhao, Huojun Zhang, Juefeng Wan, Hui Zhang, Yan Wang, Ruiyan Wu, Jingwen Wang, Wang Yang, Menglong Zhou, Shujuan Zhou, Yajie Chen, Zhiyuan Zhang, Xian Wu, Yan Xuan, Renjie Wang, Yiqun Sun, Tong Tong, Xun Zhang, Lei Wang, Dan Huang, Weiqi Sheng, Hao Yan, Xu Yang, Yuxin Shen, Yu Xu, Ruping Zhao, Miao Mo, Guoxiang Cai, Sanjun Cai, Ye Xu, Zhen Zhang
Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH). Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Ruiyan Wu, Caiqin Wang, Zhiming Li, Jian Xiao, Chunyan Li, Xuemin Wang, Pengfei Kong, Jianghua Cao, Fuxue Huang, Zhiling Li, Yun Huang, Yuhong Chen, Xuan Li, Dong Yang, Hailiang Zhang, Jia Mai, Gongkan Feng, Rong Deng, Xiaofeng Zhu
SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA. Journal for immunotherapy of cancer 8 (2) (2021)

Ruiyan Wu.css-eqlu8i{font-size:small;padding-left:4px;}